Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Formulary Coverage & PA |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy N/A

    Priority Health Medicare MPSERS Formulary (Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the Priority Health Medicare MPSERS formulary (Drug List) describing covered drugs, coverage rules, restrictions (prior authorization, step therapy, quantity limits), member rights to exceptions and transition supplies, and how members/providers can find formulary information. It affects Priority Health Medicare MPSERS plan members and their prescribers/pharmacies.

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare MPSERS Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change indicated
    Effective DateN/A
    Last ReviewApr 21, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug entry lists 'PA' to avoid coverage denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4/21/2026formulary updated on
    May 1, 2026formulary current as of
    30 daystransition supply
    72 / 24 hoursexception decision timeframe
    PA, QL, ST, LA, HIutilization controls
    T1–T6tiers defined

    Formulary Coverage & Conditions

    General formulary coverage

    Covered when ALL of the following are met

    Formulary coverage general conditions: Drug is listed on the formulary; drug is medically necessary; prescription is filled at a Priority Health Medicare network pharmacy and other plan rules are followed.

    From formulary overview

    Transition and emergency supply

    Temporary coverage provided in specified situations

    Temporary/transition supply: For drugs not on the formulary or with restrictions, members may receive a temporary 30-day supply while pursuing coverage decisions or exceptions. Long-term care residents may receive a 31-day emergency supply; transition supplies of at least 30 days are provided for members experiencing a level-of-care change.30 days

    Applies during first 90 days of membership and for specified level-of-care changes

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare MPSERS Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change indicated
    Effective DateN/A
    Last ReviewApr 21, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug entry lists 'PA' to avoid coverage denial.
    SourceLink
    On This Page
    Formulary Coverage & ConditionsFormulary Entries, Tiers & Limits (Coding Examples)Authorization, Documentation & Denial RisksFormulary Background & ScopeAbbreviations & Tier DefinitionsStep Therapy Rules & ReferencesQuantity Limits by Product / StrengthSite of Care / Benefit DesignationsBiosimilars & Interchangeable Biologics

    Formulary coverage with utilization management

    Coverage and utilization management as listed in formulary segments

    Formulary coverage statements: Each listed drug entry includes tier placement and any associated requirements/limits (PA, QL, ST, NE, LA, HI, B/D). Coverage requires meeting those requirements where specified.

    Drugs flagged with PA/ST/QL must meet those controls for coverage

    Formulary administrative coverage controls

    Coverage for listed oncology oral agents is conditional and subject to the following administrative controls

    Administrative controls: Prior authorization is required for many specialty oncology agents; specified quantity limits apply; some products designated limited availability require special handling.

    Clinical indication criteria are not provided in these segments; follow PA/QL/LA flags on each entry

    Drug-specific PA and QL examples

    Coverage and access are conditioned on the drug-specific annotations below (examples):

    Examples: PEMAZYRE: Tier 5; PA; QL (14 EA per 21 days). PIQRAY: Tier 5; PA; QL (varies by strength, e.g., 28–56 EA per 28 days). QINLOCK: Tier 5; PA; QL (90 EA per 30 days). REZDIFFRA: Tier 5; PA; QL (30 EA per 30 days).

    Each listed drug follows its PA/QL as shown in formulary entries

    Coverage stance with administrative controls

    Drugs listed are covered under the Medicare formulary subject to the following administrative controls when specified:

    Coverage with controls: If a drug is listed with a Tier and no Requirements/Limits value, it is listed on the formulary without PA/QL in this excerpt.

    Some insulin and oral agents are listed without explicit PA/QL in these chunks

    Prior Authorization required: If 'Requirements/Limits = PA' is shown for a drug, prior authorization must be obtained before coverage is approved.

    Examples include RYBELSUS and multiple insulin supplies (see formulary entries)

    Quantity limits enforced: When 'Requirements/Limits = QL (X per Y days)' is listed, the specified maximum quantity applies and claims exceeding this may be denied absent authorization.

    Examples: SYNJARDY XR QL 30 or 60 EA per 30 days; XARELTO suspension QL 620 ML per 30 days

    Formulary Coverage with Limits

    Coverage is formulary-tier dependent with additional PA or QL requirements as noted for specific products.

    Formulary coverage rules: Drug coverage and restrictions depend on listed Tier and any associated Requirements/Limits (QL) or PA noted in the formulary entries.

    Prescribers must follow PA and QL limits where specified

    Formulary coverage with product-specific utilization management

    Formulary coverage and requirements as stated per product entry

    Formulary product rules: Each listed product has a tier and may have one or more utilization management designations (PA, QL, ST, ED, LA, HI, B/D). Coverage follows tier placement and these specified requirements.

    Examples and specifics are itemized per product entry in the formulary

    Formulary Tiering and Requirements

    Coverage/tiering and stated requirements as listed for individual drugs

    Formulary listing requirements: Drug is assigned a tier and may have Requirements/Limits (PA, QL, B/D, LA); coverage is governed by the plan rules indicated on the formulary.

    Specific clinical criteria for PA are not present in this extract; follow listed flags

    General coverage criteria for listed agents

    Coverage depends on drug-specific tier and may require PA and/or be subject to quantity limits

    General formulary rules: Drugs are assigned tiers (T1–T6); specialty Tier 5 drugs are limited to 30-day supply and many require prior authorization (PA) and/or have quantity limits (QL).

    Derived from multiple entries listing Tier, PA, and QL flags

    In this formulary, an Excluded Drug (ED) is a prescription product that is not normally covered by a Medicare Prescription Drug Plan. Costs paid by the enrollee for an ED do not count toward the member’s total drug spend and therefore do not help the member qualify for catastrophic coverage; members receiving extra help will not get assistance for ED products.

    The document uses the ED designation in the formulary entries and legend to indicate specific products that are excluded from coverage. Examples in the extract include topical and supplement products and selected oral agents where the Requirements/Limits column explicitly lists ED; those items are not covered and are identified in the formulary entries where shown.

    Within several segments of this extract the abbreviation ED appears in the formulary legend, but there are portions where no individual drugs in that excerpt are labeled ED. Where no explicit ED entries appear in a segment, the legend still applies to the full formulary outside this partial extract.

    The formulary legend lists ED (Excluded Drug) among other key abbreviations; in this excerpt the legend references ED but the immediate product listings in that page may not apply the ED flag to any specific entries shown here.

    Note that Tier 5 (specialty) drugs are subject to a 30‑day supply limit per the formulary note. The ED abbreviation is defined in the legend and used elsewhere in the document to mark excluded drugs; in this extract the tier supply rule and ED definition are presented together in the legend.

    In multiple pages of this extract the ED abbreviation is defined, yet specific excluded products are not present in the immediate listings shown. Where no product is annotated ED in the extract, no exclusion action is applied within that excerpt.

    The abbreviation key in this portion reiterates ED = Excluded Drug, but the specific product lines on these pages do not all include ED markings; absence of the ED flag in an excerpt indicates no explicit exclusions listed on those pages.

    Across several formulary segments the ED abbreviation appears in the key; however, this partial extract contains areas where no explicit excluded drugs are called out — the ED legend remains applicable to the full formulary but may not be applied on every page of the extract.

    Some specific products in the document are explicitly marked ED. For example, entries in the dermatologic and vitamin/supplement sections list particular items (e.g., certain topical preparations and multiple vitamin formulations) with Requirements/Limits = ED, indicating those products are excluded from coverage where so annotated.

    When an entry’s Requirements/Limits column shows ED, that product is excluded from coverage under the plan. The extract includes multiple such entries (notably vitamins, select topical products, and other listed items) that are labeled ED and therefore will not be covered.

    The formulary legend (appearing on multiple pages) reiterates that ED denotes an Excluded Drug. In the specific extract shown on some pages, there are no active ED annotations in the immediate product list, though the legend continues to define the abbreviation for the wider formulary.

    Certain product groups in the extract show examples of items marked ED (e.g., phenazopyridine formulations, chorionic gonadotropin/injectable fertility products, and some inhalation/nebulized solutions). These entries, where annotated ED, are not covered by the plan.

    This extract does not include explicit determinations of 'Not Medically Necessary' (NMN) for any drugs. The document uses other designations (PA, QL, ST, LA, ED) to indicate utilization controls and exclusions; NMN statements are not present in these chunks.

    The portions of the formulary provided here do not contain explicit 'not medically necessary' (NMN) findings. The extract instead contains Excluded Drug (ED) flags and utilization management annotations; no NMN statements appear in these pages.

    Review of the provided excerpt shows no explicit 'not medically necessary' language for any listed drugs. Coverage decisions in this extract are conveyed via tier designations and requirement flags (PA, QL, ED, etc.), not NMN statements.

    Formulary Entries, Tiers & Limits (Coding Examples)

    Formulary designationsmixed
    B/DPart B vs. Part D designation; may require physician-provided information on use and setting to determine coverage
    Selected drug entries with tier and limits as listedmixed
    fentanyl transdermal patch 72 hour 12 mcg/hrlisted with drug tier = 4 and QL (10 EA per 30 days)
    fentanyl transdermal patch 72 hour 25 mcg/hrlisted with drug tier = 4 and QL (10 EA per 30 days)
    fentanyl transdermal patch 72 hour 50 mcg/hrlisted with drug tier = 4 and QL (10 EA per 30 days)
    fentanyl transdermal patch 72 hour 75 mcg/hrlisted with drug tier = 4 and QL (10 EA per 30 days)
    ARIKAYCEDrug Tiers = 5; Requirements/Limits = PA; QL (235.2 ML per 28 days)
    lidocaine external patch 5%Drug Tiers = 3; Requirements/Limits = PA; QL (90 EA per 30 days)
    LIDOCANDrug Tiers = 3; Requirements/Limits = PA; QL (90 EA per 30 days)
    KLOXXADODrug Tiers = 4; Requirements/Limits = QL (2 EA per 30 days)
    naloxone (various forms)tiers 1-2 and QL as specified per formulation
    vancomycin HCl IV 1 gm, 500 mgDrug Tiers = 3; Requirements/Limits = HI
    1–10 of 11
    1/2
    Sample listed drugs and strengthsmixed
    lomustine 10 mg, 40 mg, 100 mglomustine oral capsule strengths listed
    MATULANElomustine brand
    VALCHLORtopical mechlorethamine listed with PA; LA; QL (60 GM per 30 days)
    abiraterone acetate 250 mgantiandrogen oral tablet; QL (120 EA per 30 days)
    bicalutamideantiandrogen
    ERLEADA 240 mg, 60 mgrequirements: PA; QL (30 EA/30 days for 240 mg; 120 EA/30 days for 60 mg)
    Additional oncology/targeted agentsmixed
    XPOVIO (various dosing packs)multiple regimen listings with PA; QL (various EA per 28 days)
    ZOLINZAPA; QL (120 EA per 30 days)
    anastrozole, exemestane, letrozoleAromatase inhibitors listed with tiers
    Formulary administrative codes and examplesmixed
    QL (30 EA per 30 days)Quantity limit example from XIGDUO XR and other oral tablets
    QL (2 ML per 28 days)Quantity limit example for injectable presentations (e.g., some GLP-1s)
    QL (60 ML per 30 days)Quantity limit example for enoxaparin prefilled syringes
    PAPrior Authorization required
    B/DPart B vs Part D designation
    Selected formulary product entries (examples)mixed
    OTEZLA ORAL TABLET 30 MGTier 5; Requirements/Limits = PA; QL (60 EA per 30 days)
    PANRETINTier 5; Requirements/Limits = PA; QL (60 GM per 30 days)
    fluorouracil external cream 5%Tier 2; QL (40 GM per 30 days)
    tacrolimus external ointmentTier 4; QL (100 GM per 30 days)
    calcipotriene external cream/ointment/solutionTiers 2-3; QL (120 GM or ML per 30 days)
    imiquimod external cream 5%Tier 4
    sulfur/sulfide topical products (selenium sulfide)Tiers 2-3; some excluded (ED) entries
    RELISTOR ORALTier 5; PA; QL (90 EA per 30 days)
    LOKELMA ORAL PACKET 10 GMTier 3; QL (90 EA per 30 days)
    LOKELMA ORAL PACKET 5 GMTier 3; QL (30 EA per 30 days)
    1–10 of 19
    1/2
    Listed formulations and strengths (non-exhaustive in extract)mixed
    80 MGFIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG (strength listed)
    60 MG/0.2ML, 90 MG/0.3MLSOMATULINE DEPOT SUBCUTANEOUS SOLUTION (strengths listed)
    45 MG/0.5MLustekinumab-aekn subcutaneous solution prefilled syringe (strength listed)
    200 MG/1.14ML, 300 MG/2ML, 100 MG/0.67MLDUPIXENT formulations (strengths listed)
    360 ML per 30 daysRINVOQ LQ quantity limit specified
    Quantity Limits examples
    Common oral tablet QL examples30 EA per 30 days; 60 EA per 30 days; 90 EA per 30 days
    Liquid/solution QL examples235.2 ML per 28 days; 900 ML per 30 days; 1200 ML per 30 days
    Topical/cream QL examples750 ML per 30 days (VIGAFYDE as example); 100 GM per 30 days (tacrolimus ointment)
    Quantity limits examples (various segments)
    Epilepsy / antiepileptic exampleseslicarbazepine acetate 200/400 mg — QL 30 EA per 30 days; 600/800 mg — QL 60 EA per 30 days
    CNS / dementia examplesdonepezil 10 mg tablet — QL 60 EA per 30 days; memantine oral solution — QL 300 ML per 30 days
    Migraine / CGRP agentsAIMOVIG — QL 1 ML per 30 days; EMGALITY — QL 2–3 ML per 30 days (depending on dose)
    Example quantity limits — XPOVIO regimens
    XPOVIO regimen rangeQL varies by dosing pack/regimen — examples: 4 to 32 EA per 28 days depending on regimen
    Specific pack examples40 mg once weekly packs QL 8 EA per 28 days; 60 mg once weekly pack QL 4 EA per 28 days
    Alternate regimens40 mg twice weekly or 80 mg regimens have distinct QL values (e.g., 16–24 EA per 28 days) depending on pack
    Abiraterone quantity limit example
    Abiraterone acetate QL120 EA per 30 days
    Related antiandrogen examplesERLEADA 240 mg — QL 30 EA per 30 days; ERLEADA 60 mg — QL 120 EA per 30 days
    Tiering noteListed as Tier 5 specialty agents in formulary segments where applicable
    Example QL values vary by product
    General variability by productQL values differ by formulation/strength (examples: 30 EA/30 days; 60 EA/30 days; 2 ML per 28 days for injectables; up to 620 ML per 30 days for XARELTO suspension)
    Insulin/pen needle examplesSome insulin supplies and pen needles list PA and QL (examples shown elsewhere in formulary)
    Enoxaparin suspension examplesEnoxaparin prefilled syringes QL varies by strength (examples shown in document)
    Quantity Limits examples (cardiovascular excerpt)
    High-volume oral tablet QLs (cardiovascular)benazepril 5 mg — QL 480 EA per 30 days; benazepril 20 mg — QL 120 EA per 30 days; amlodipine combinations — QL 30–120 EA per 30 days depending on strength
    ACE inhibitor examplesenalapril 2.5 mg — QL 480 EA per 30 days; enalapril 10 mg — QL 120 EA per 30 days
    Sacubitril-valsartansacubitril-valsartan 24–26 mg — QL 90 EA per 30 days
    Quantity limits examples (statins and strengths)
    Rosuvastatin 5/10 mgQL 120 EA per 30 days
    Rosuvastatin 20 mgQL 60 EA per 30 days
    Rosuvastatin 40 mgQL 30 EA per 30 days
    Simvastatin strength examplesSimvastatin 5/10/20 mg — QL 120 EA per 30 days; 40 mg — QL 60 EA; 80 mg — QL 30 EA per 30 days
    Quantity Limits examples (various products)
    Selected varied QL examplesXARELTO 10 mg tablets — QL 30 EA per 30 days; XARELTO suspension — QL 620 ML per 30 days; enoxaparin prefilled syringes — QL varies by strength (e.g., 60 ML, 48 ML, 18 ML per 30 days); benazepril 5 mg — QL 480 EA per 30 days
    ENTRESTO sprinkleENTRESTO oral capsule sprinkle — QL 240 EA per 30 days
    RYBELSUSRYBELSUS — QL 30 EA per 30 days
    Quantity Limits examples (biologics)
    COSENTYX QL8 ML per 28 days
    DUPIXENT QL by presentation3.42 ML or 8 ML per 30 days depending on formulation
    SKYRIZI QL1 ML per 28 days or 1.2/2.4 ML per 56 days for cartridges
    Sample quantity limits (cystic fibrosis / pulmonary examples)
    Epinephrine auto-injectorQL 4 EA per 30 days
    KALYDECO (CF)QL 56 EA per 28 days
    TRIKAFTA therapy packQL 84 EA per 28 days (therapy pack) or 56 EA per 28 days for other pack),
    OFEV (pulmonary fibrosis)QL 60 EA per 30 days

    Authorization, Documentation & Denial Risks

    Prior Authorization

    Provide clinical info for PA and B/D determinations

    Prescriber must provide clinical details when a drug is designated B/D (Part B vs Part D) or when a PA is required; physician-submitted information may be needed to determine benefit responsibility and to obtain prior authorization.

    • If B/D is shown, the physician must describe the drug's intended use and setting to determine Part B vs Part D coverage.
    • Prior authorization must be obtained for drugs marked PA before the plan will cover them.
    Prior Authorization

    Obtain PA for listed PA-marked formulations

    Request prior authorization for any drug entry labeled 'PA' (examples in the formulary include lidocaine patch 5% and LIDOCAN products); submit the PA per Priority Health Medicare procedures before dispensing.

    • Lidocaine external patch 5% — Requirements/Limits = PA; QL (90 EA per 30 days).
    • LIDOCAN and LIDOCAN III entries are listed with Requirements/Limits = PA; QL (90 EA per 30 days).
    Prior Authorization

    PA required for specialty/non-preferred drugs

    Obtain prior authorization for specialty and non-preferred high-tier drugs marked PA (e.g., AUVELITY, EXXUA, ZURZUVAE); claims require PA approval before payment.

    • AUVELITY — Requirements/Limits = PA; QL (60 EA per 30 days).
    • EXXUA — Requirements/Limits = PA; QL (30 EA per 30 days); ZURZUVAE — Requirements/Limits = PA.
    Prior Authorization

    PA required for many oncology oral agents

    Many oral oncology agents are subject to prior authorization and associated quantity limits; prescribers must request PA prior to dispensing for coverage to be approved.

    • Examples: PEMAZYRE, PIQRAY, QINLOCK and numerous other Tier 5 oncology oral agents list Requirements/Limits = PA and specific QL values.
    • Some oncology products also display Limited Availability (LA) and must follow special handling.
    Prior Authorization

    Get PA and follow QL for Tier 5 specialty drugs

    Prior authorization is required for numerous Tier 5 specialty drugs; also confirm and adhere to listed quantity limits (QL) when submitting PA requests.

    • Examples: PEMAZYRE — PA; QL (14 EA per 21 days). PIQRAY — PA; QL varies by strength. QINLOCK — PA; QL (90 EA per 30 days).
    Prior Authorization

    Secure PA for insulin supplies, pen needles, and specified oral agents

    Drugs with 'Requirements/Limits = PA' listed (including certain insulin supplies, pen needles, and oral agents such as RYBELSUS) require prior authorization before coverage.

    • RYBELSUS — Requirements/Limits = PA; QL (30 EA per 30 days).
    • Embecta pen needles and other insulin supplies are listed with Requirements/Limits = PA.
    Prior Authorization

    PA required for selected specialty/high-cost meds

    Obtain prior authorization for selected specialty or high-cost medications identified in the formulary (examples include REDEMPLO, REPATHA presentations, NEXLETOL and NEXLIZET).

    • REPATHA (various presentations) — Requirements/Limits = PA; QL (2 ML per 28 days; Pushtronex 3.5 ML per 30 days).
    • NEXLETOL and NEXLIZET — Requirements/Limits = PA; QL (30 EA per 30 days).
    Prior Authorization

    Submit PA for all PA‑marked drugs

    Any drug entry explicitly labeled 'PA' in the formulary requires prior authorization before coverage; prescribers must submit PA to avoid non-coverage.

    • Examples include NEXLETOL, NEXLIZET, REPATHA formulations and many specialty agents marked with PA.
    • PA must be approved prior to dispensing for coverage to be provided.
    Prior Authorization

    PA required for select dermatology and specialty agents

    Obtain prior authorization for listed products such as OTEZLA (PA; QL 60 EA/30 days) and PANRETIN (PA; QL 60 GM/30 days) as indicated in the formulary.

    • OTEZLA ORAL TABLET 30 MG — Requirements/Limits = PA; QL (60 EA per 30 days).
    • PANRETIN — Requirements/Limits = PA; QL (60 GM per 30 days).
    Prior Authorization

    PA required for certain high-cost hormonal and metabolic products

    Request prior authorization for high-cost or specialized therapies noted in the formulary (examples include VYNDAMAX, INCRELEX, ACTHAR) per the Requirements/Limits column.

    • VYNDAMAX — Requirements/Limits = PA; QL (30 EA per 30 days).
    • INCRELEX — Requirements/Limits = PA; LA. ACTHAR — Requirements/Limits = PA (listed among hormonal agents).
    Prior Authorization

    PA required for specialty biologics (e.g., COSENTYX, DUPIXENT, SKYRIZI)

    Many specialty biologics and immunomodulators require prior authorization; verify PA and quantity limits for agents such as COSENTYX, DUPIXENT, SKYRIZI and similar biologics before prescribing.

    • COSENTYX (300 mg) — Requirements/Limits = PA; QL (8 ML per 28 days).
    • DUPIXENT and SKYRIZI presentations — Requirements/Limits = PA; QL specified per formulation.
    Prior Authorization

    PA required for pulmonary and cystic fibrosis specialty agents

    Prior authorization is required for select pulmonary and cystic fibrosis specialty agents; follow PA procedures and note any B/D or LA designations affecting benefit/payment.

    • CAYSTON — Requirements/Limits = PA; LA. KALYDECO — Requirements/Limits = PA; QL (56 EA per 28 days). TRIKAFTA — Requirements/Limits = PA; QL (84 EA per 28 days).
    • PULMOZYME — Requirements/Limits = B/D (Part B vs Part D) for inhalation solution).
    Step Therapy

    Meet step therapy prior to coverage

    Prescribers may be required to try specified first‑line (preferred) drugs before the plan will cover alternative agents; step therapy must be satisfied per the formulary where ST is indicated.

    • If ST is listed, the member must trial the required agent(s) and fail or be intolerant before the alternate is covered.
    • Step therapy rules are available in the formulary and online step therapy documents.
    Step Therapy

    Document prior trials when ST applies

    When 'ST' (Step Therapy) appears in the formulary, members must generally trial preferred agents first; prescribers should document prior trials when requesting coverage of non‑preferred drugs.

    • Examples of ST applications include some antidepressants and other therapeutic classes listed with ST.
    • Provide documentation of prior trial and failure/intolerance when submitting an exception or PA.
    Step Therapy

    Step therapy applies to select antidepressants (FETZIMA, TRINTELLIX, vilazodone)

    Certain agents are expressly subject to step therapy in the formulary (examples: FETZIMA, TRINTELLIX, vilazodone); prescribers must follow ST requirements and document trials of preferred agents.

    • FETZIMA — Requirements/Limits = ST; QL (30 EA per 30 days). TRINTELLIX — Requirements/Limits = ST; QL (30 EA per 30 days).
    • Vilazodone — Requirements/Limits = ST; QL (30 EA per 30 days).
    Note

    Recognize 'ST' in the formulary key

    The formulary legend uses the abbreviation 'ST' to denote Step Therapy; treat this as the recognized step therapy indicator when reviewing formulary entries.

    • 'ST' is defined in the abbreviations/key and indicates a step therapy requirement where applied to a product entry.
    Step Therapy

    Paliperidone ER requires ST and QL adherence

    Paliperidone ER extended‑release oral tablet entries note Step Therapy (ST) and specific quantity limits; prescribers must follow those ST requirements when requesting coverage.

    • Paliperidone ER — Requirements/Limits = ST; QL (30 EA per 30 days for some strengths; 60 EA for others).
    Note

    Check full formulary for ST details when abbreviation present

    The formulary includes 'ST' references in the abbreviations, but some excerpts do not list specific step‑therapy rules; consult the full formulary or step therapy documents for details.

    • Where ST is indicated on the full glossary, specific step rules may apply though not shown in every excerpt.
    Note

    ST referenced in abbreviations — verify specifics elsewhere

    The formulary legend and some product lines reference Step Therapy (ST) but not all excerpts include the full ST steps; verify the full formulary or policy documents for step details.

    • ST is referenced in the abbreviations but specific step requirements may not be present in every extract.
    Step Therapy

    Comply with ST when applied (e.g., calcitriol external)

    Where 'ST' is noted for a product (e.g., calcitriol external), prescribers must comply with the step therapy requirement prior to coverage of non‑preferred alternatives.

    • Calcitriol external — Requirements/Limits = ST. Provide documentation of prior trial per ST when requesting coverage.
    Note

    Review full formulary for ST application when not shown

    The formulary legend includes 'ST' but some product listings in this extract show no specific ST rules; prescribers must review the full formulary for step therapy applicability.

    • Document indicates 'ST' in the key but this partial extract lacks explicit step therapy steps for many listed drugs.
    Note

    ST defined in formulary key — follow where indicated

    The formulary key defines ST (Step Therapy) as an authorization control; where ST is designated for a product you must follow step requirements or submit documentation for exception.

    • ST is defined in the Requirement abbreviations and must be followed where applied to a product entry.
    Step Therapy

    Follow ST or request an exception with documentation

    ST is listed in the formulary legend; if a specific product entry includes 'ST', prescribers must meet those step therapy requirements or request an exception with supporting documentation.

    • The legend lists ST; specific ST requirements may be found in product entries or the full step therapy policy.
    Note
    Documentation Required

    Provide prescriber's supporting medical statement for exceptions

    When requesting an exception, the prescriber must provide a supporting medical statement explaining why the member needs the exception; decisions are generally made within 72 hours (24 hours if expedited).

    • Include clinical justification from the prescriber describing why alternative formulary options are not suitable.
    • Standard decision timeframe = 72 hours; expedited decisions = 24 hours if criteria for urgency are met.
    Documentation Required

    Submit clinical info to determine Part B vs Part D (B/D)

    If Part B vs Part D coverage is ambiguous (B/D), the physician should submit information describing the drug's use and setting to determine benefit responsibility.

    • B/D designation may require physician-submitted details to determine whether the drug is covered under Medicare Part B or Part D.
    • Submit documentation of intended use/setting with the PA or benefit determination request.
    Documentation Required

    Provide documentation to meet PA, QL, and ST requirements

    Prescribers must supply documentation to satisfy prior authorization (PA) requirements and to support requests that exceed quantity limits (QL) or override step therapy (ST) when requesting coverage.

    • If a drug entry lists 'PA', include relevant clinical notes, diagnoses, prior therapy and rationale.
    • Document dose, frequency, and justification when requesting overrides of QL or ST.
    Documentation Required

    Document justification for PA/QL/LA/HI requests

    When requesting authorization or overrides, provide clinical information justifying exceeding quantity limits or requesting handling for Limited Availability (LA) or Home Infusion (HI).

    • Document why the requested quantity exceeds the QL and include clinical rationale and dosing schedule.
    • For LA or HI products, include distribution/setting needs and justification.
    Documentation Required

    Attach documentation when prescribing PA‑listed drugs

    Include supporting clinical documentation with prescriptions for any drug entry that lists 'PA'; ensure documentation aligns with the product's stated quantity limits and rationale for use.

    • PA entries must be accompanied by clinical justification and any required diagnostic or prior-treatment evidence.
    • Confirm QL values in the formulary and include dosing details in the PA submission.
    Documentation Required

    Document dose/frequency for QL drugs (e.g., RYBELSUS)

    Document the dose and frequency when prescribing drugs with quantity limits (example: RYBELSUS QL 30 EA per 30 days); provide this information if requesting an override.

    • RYBELSUS — QL (30 EA per 30 days); include prescribed dose and intended frequency when seeking coverage or an exception.
    Documentation Required

    Submit clinical support with PA for specialty agents (REPATHA, NEXLETOL, KERENDIA)

    Provide supporting clinical records for prior authorization requests for specialty therapies (examples in the formulary: REPATHA, NEXLETOL, NEXLIZET, KERENDIA); include diagnosis, prior treatments, and dosing.

    • REPATHA — PA; QL (2 ML per 28 days or Pushtronex 3.5 ML per 30 days).
    • NEXLETOL/NEXLIZET — PA required; include lipid management history and rationale.
    Billing Rule

    Follow quantity limits for strengths/formulations

    Adhere to specified quantity limits for strengths and formulations; claims exceeding listed QL values may be denied without an approved authorization.

    • Rosuvastatin 5/10 mg — QL (120 EA per 30 days); 20 mg — QL (60 EA per 30 days); 40 mg — QL (30 EA per 30 days).
    • REPATHA formulations — QL per presentation (2 ML per 28 days; Pushtronex 3.5 ML per 30 days).
    Documentation Required

    Provide required documentation per formulary indicators (PA/QL/ST/LA/HI/ED)

    When an authorization type is listed (PA, QL, ST, LA, HI, ED), include the corresponding documentation and follow the formulary key; these indicators reflect required claims/benefit documentation.

    • Formulary abbreviations define required controls (PA, QL, ST, LA, HI, ED); include required documentation per the key when submitting requests.
    • ED = Excluded Drug (not covered); HI = Home Infusion; B/D = Part B vs Part D — may affect benefit responsibility.
    Billing Rule

    Follow formulary requirement indicators on claims and PA submissions

    Formulary entries include indicators (PA, QL, B/D, LA) that must be followed; prescribers should ensure claims reflect these requirements to prevent coverage issues.

    • Check the Requirements/Limits column for PA, QL, B/D or LA designations before submitting prescriptions.
    • Include relevant clinical and billing details with PA submissions to align with plan rules.
    Documentation Required

    Document per QL and PA examples when submitting claims

    Quantity limits and prior authorization are specified for many products (examples: epinephrine auto-injector QL 4 EA/30 days; KALYDECO PA; QL 56 EA/28 days); provide documentation consistent with these limits when requesting coverage.

    • Epinephrine auto‑injector — QL (4 EA per 30 days).
    • KALYDECO — PA required; QL (56 EA per 28 days).
    Note
    Denial Risk

    Risk of non‑coverage if PA not obtained

    Failure to obtain required prior authorization may result in Priority Health Medicare denying coverage for the drug; prescribers must secure PA before dispensing PA‑designated drugs.

    • If prior authorization is not obtained for PA‑required drugs, Priority Health Medicare may not cover the medication.
    Denial Risk

    PA not obtained may cause denial of coverage

    If prior authorization is not secured, Priority Health Medicare may deny payment for the medication; ensure PA is in place to avoid non‑coverage.

    • Failure to obtain PA may result in the plan not covering the drug.
    Denial Risk

    PA/QL/ST enforce coverage at claim adjudication

    Drugs marked with PA, QL, or ST will trigger authorization or quantity enforcement at claim adjudication; meet those requirements to avoid denial.

    • PA or QL indicators on a formulary entry will be enforced during adjudication and may require an approved PA or override.
    • ST entries require documentation of prior trials before coverage will be allowed.
    Denial Risk

    PA/QL/LA noncompliance may lead to denial for oncology agents

    Coverage for many specialty oncology agents can be denied without prior authorization; quantity limits and limited availability designations also impact coverage decisions.

    • Specialty oncology oral agents frequently list PA and QL — obtain PA and adhere to QL to avoid denial.
    • LA designations may restrict where a drug is available and require special handling.
    Denial Risk

    Failure to obtain PA or exceed QL may cause denial

    Requests for specialty drugs submitted without prior authorization or that exceed quantity limits may be denied per the formulary; secure PA and document clinical need when limits are exceeded.

    • Many Tier 5 specialty drugs list PA and QL; claims without approved PA or exceeding QL are subject to denial.
    • Examples include PIQRAY, PEMAZYRE, QINLOCK with specific QL values.
    Denial Risk

    PA required for certain listed drugs to avoid denial

    Coverage may be denied unless prior authorization is obtained for drugs where the Requirements/Limits column lists 'PA' (examples: RYBELSUS, various insulin supplies and pen needles).

    • RYBELSUS — PA required; QL (30 EA per 30 days).
    • Multiple insulin supplies and pen needles in the formulary show Requirements/Limits = PA.
    Denial Risk

    PA and QL enforcement may result in denial for certain specialty agents

    Requests for certain specialty agents (REPATHA, NEXLETOL, NEXLIZET, KERENDIA, REDEMPLO, TRYNGOLZA) may be denied if prior authorization requirements are not met or quantity limits are exceeded.

    • REPATHA — PA required; QL varies by presentation. KERENDIA — PA; QL (30 EA per 30 days).
    • Supply and prior authorization conditions must be met for coverage.
    Denial Risk

    PA‑marked medications require approved PA prior to coverage

    Medications marked 'PA' must have prior authorization approved before the plan will cover them; submit PA documentation to prevent coverage denial.

    • Examples: NEXLETOL, NEXLIZET, REPATHA products and many MS agents are listed with PA.
    • PA must be approved for these products prior to dispensing to secure coverage.
    Denial Risk

    ED entries are excluded and may be denied if billed

    Drugs designated 'ED' (Excluded Drug) are not covered under the Medicare Prescription Drug Plan and will be denied if billed to the plan.

    • ED entries in the formulary indicate exclusion from coverage and do not count toward drug spend or catastrophic coverage.
    Denial Risk

    Tier 5 specialty drugs limited to 30‑day supply — risk of denial if exceeded

    Tier 5 specialty drugs are limited to a 30‑day supply; requests exceeding that supply or submitted without required PA/QL may be denied.

    • Note: Tier 5 drugs are specialty and are limited to 30‑day supply only per the formulary.
    • Obtain PA and adhere to QL to avoid denial for Tier 5 products.
    Denial Risk

    ED‑designated drugs will not be covered

    Excluded drugs (ED) listed in the formulary will not be covered and claims for ED products may be denied.

    • ED designation removes coverage under the Medicare Prescription Drug Plan; verify coverage before prescribing.
    Denial Risk

    PA required — risk of denial without approved authorization

    Drugs marked 'PA' require prior authorization and may be denied without an approved authorization; submit PA before dispensing to ensure coverage.

    • Examples include INCRELEX and multiple hormonal/biologic agents with Requirements/Limits = PA; LA.
    • PA status must be verified and approved prior to claim submission.
    Prior Authorization

    PA/QL commonly required for specialty drugs — obtain PA and follow QL

    Specialty drugs in the formulary commonly list PA and/or QL; prescribers must request PA and observe QL values for these products to obtain coverage.

    • Many specialty and high-tier drugs (e.g., SOMAVERT, SIGNIFOR, COSENTYX, DUPIXENT) require prior authorization.
    • Check QL and PA indicators before prescribing to avoid claim rejection.
    Prior Authorization

    PA required for specialty pulmonary and CF agents

    Prior authorization is required for many specialty pulmonary and cystic fibrosis agents (examples: CAYSTON, KALYDECO, TRIKAFTA); absence of PA may lead to coverage denial.

    • CAYSTON — Requirements/Limits = PA; LA. KALYDECO — Requirements/Limits = PA; QL (56 EA per 28 days). TRIKAFTA — Requirements/Limits = PA; QL (84 EA per 28 days).

    Formulary Background & Scope

    The formulary groups drugs by medical condition and lists both brand and generic names. The legend and background explain coverage controls (PA, QL, ST, LA, ED) and where they apply; excluded drugs are defined in the key and are treated as not covered when annotated.

    Abbreviations & Tier Definitions

    Generic drugs definition
    Definition: Generic drugsFDA‑approved products with the same active ingredient as brand name drugs; may be substituted per state law
    Cost and substitution noteGeneric drugs usually cost less and can often be substituted without a new prescription depending on state laws
    Formulary coveragePriority Health Medicare covers both brand name and generic drugs; substitution rules depend on state law
    Biologics / Biosimilars
    Biologics vs biosimilarsBiological products are complex drugs; biosimilars are alternatives to originals and may be interchangeable per state law
    Substitution rulesSome biosimilars are interchangeable and, depending on state law, may be substituted without a new prescription
    Cost noteBiosimilars may cost less than the original biological product
    B/D — Part B vs Part D
    B/D meaningPart B vs. Part D designation — determines benefit responsibility; physician documentation may be required to determine setting/use
    ImplicationDrugs with B/D may require submission of clinical information to adjudicate Part B vs Part D coverage
    Contact noteSee formulary and provider instructions for required documentation
    ED — Excluded Drug
    ED (Excluded Drug)A drug labeled ED is not normally covered by the Medicare Prescription Drug Plan and does not count toward total drug spend or extra help
    Coverage impactClaims for ED products may be denied; member cost not applied to catastrophic coverage threshold
    Examples in formularySpecific ED entries appear in the formulary where applicable
    HI — Home Infusion
    HI (Home Infusion)Home Infusion: drug may be covered under the medical benefit; contact CustomerCare for details (844.403.0847)
    When usedHI designation applies to some parenteral/infusion products listed in the formulary
    Provider actionProviders should contact CustomerCare for coverage and site-of-care guidance
    PA / QL / ST / LA / NE abbreviations
    PAPrior Authorization — approval required before coverage; failure to obtain PA may result in denial
    QLQuantity Limit — maximum units allowed per specified period (e.g., EA per 30 days, ML per 30 days)
    ST / LA / NEST = Step Therapy; LA = Limited Availability; NE = No Express Scripts
    Abbreviations summary
    Tier and abbreviation keyT1–T6 denote tiers; PA = Prior Authorization; QL = Quantity Limits; ST = Step Therapy; NE = No Express Scripts; LA = Limited Availability; HI = Home Infusion
    Units abbreviationsEA = Each; ML = Milliliters; GM = Grams; B/D = Part B vs. Part D; ED = Excluded Drug
    PA definition
    PA definitionPrior Authorization — coverage requires approval prior to dispensing
    Operational impactNot obtaining PA may result in the plan not covering the drug
    DocumentationPrescribers must submit required documentation when PA is indicated
    QL definition
    QL definitionQuantity Limits — maximum units allowed per specified time period (e.g., EA per 30 days)
    Examples of unitsEA (each), ML (milliliters), GM (grams)
    EnforcementClaims exceeding QL may be denied absent authorization
    LA definition
    LA definitionLimited Availability — product may only be available at certain pharmacies or limited distribution
    ImplicationLA-designated drugs may require special handling or pharmacy routing
    ContactSee Pharmacy Directory or call CustomerCare for availability
    T5 — Specialty tier definition
    T5 — Specialty tierTier 5 denotes specialty drugs; Tier 5 drugs are limited to a 30‑day supply
    Supply restrictionRequests exceeding supply limits may be denied without PA/QL compliance
    Common controlsMany T5 agents also require PA and/or have QL or LA designations
    Abbreviations list (PA, QL, ST, LA, B/D, ED, EA)
    Common abbreviations listPA = Prior Authorization; QL = Quantity Limits; ST = Step Therapy; LA = Limited Availability; B/D = Part B vs. Part D; ED = Excluded Drug; EA = Each
    Where foundAbbreviations appear in formulary legend and per‑product entries
    UseAbbreviations indicate documentation/coverage actions required
    PA definition (repeated)
    PA (concise)Prior Authorization — authorization required before coverage
    When appliedCommon for many specialty agents and select formulations (e.g., insulin supplies, pen needles, high-cost biologics)
    ConsequenceCoverage may be denied if PA not obtained
    QL definition (repeated)
    QL (concise)Quantity Limits — maximum allowed per time period (e.g., EA per 30 days or ML per 30 days)
    ApplicationSpecified per product/strength in formulary entries
    OverrideRequests exceeding QL require documentation/PA to consider override
    T1–T6 tiers summary
    Tiers T1–T6T1 Preferred generic; T2 Generic; T3 Preferred brand; T4 Non‑preferred; T5 Specialty; T6 Infertility
    Tier effectTier determines member cost‑sharing and applicable utilization controls may vary by tier
    Tier 5 supply noteTier 5 drugs are limited to a 30‑day supply
    Abbreviations summary (low importance)
    Abbreviations and unitsT1–T6 tiers; QL = Quantity Limits; PA = Prior Authorization; ST = Step Therapy; EA = Each; HI = Home Infusion
    Document updateFormulary updated 4/21/2026 (legend appears across sections)
    ReferenceSee formulary legend for full abbreviation meanings
    PA (low importance)
    PA (short)Prior Authorization — coverage requires prior approval
    QL (short)Quantity Limits — maximum allowed per specified period (e.g., 30 days)
    Tiers (short)T1–T6 as defined in legend
    QL (low importance)
    QL (short)Maximum quantity allowed per specified period (e.g., 30 days)
    ExamplesEA per 30 days, ML per 30 days, GM per 30 days
    EnforcementClaims exceeding QL may be denied without prior authorization
    T1-T6 (low importance)
    T1–T6 tiers (concise)Formulary tiers: T1 Preferred generic; T2 Generic; T3 Preferred brand; T4 Non‑preferred; T5 Specialty; T6 Infertility
    Tier implicationsTier affects coverage rules and supply limits (e.g., T5 = 30‑day limit)
    Where listedTier appears with each drug entry in the formulary
    ED (low importance)
    ED (concise)Excluded Drug — product excluded from coverage; claims may be denied and costs do not count toward total drug spend
    Formulary markingED appears in requirements/limits column for excluded items
    ActionProviders/members should verify ED status before dispensing/billing
    Tier definitions and abbreviations (low importance)
    Tier definitions quickT1 Preferred generic; T2 Generic; T3 Preferred brand; T4 Non‑preferred; T5 Specialty; T6 Infertility
    Other abbreviationsPA, QL, ST, LA, B/D, ED, NE, HI
    Supply noteTier 5 drugs are limited to 30‑day supply
    PA / QL / LA definitions (low importance)
    PA (glossary)Prior Authorization — approval required prior to coverage
    QL (glossary)Quantity Limits — maximum allowed per stated period
    LA (glossary)Limited Availability — restricted distribution/limited supply
    ED / NE / B/D (low importance)
    ED (glossary)Excluded Drug — product excluded from coverage
    NE (glossary)No Express Scripts — not available at Express Scripts Home Delivery
    B/DPart B vs Part D designation
    Tiers (low importance)
    Tiers summaryT1 Preferred generic; T2 Generic; T3 Preferred brand; T4 Non‑preferred; T5 Specialty; T6 Infertility
    Legend locationAbbreviations and tier definitions appear in the formulary legend
    Update dateFormulary updated 4/21/2026
    Requirement abbreviations (low importance)
    Requirement abbreviationsB/D = Part B vs. Part D; PA = Prior Authorization; QL = Quantity Limits; LA = Limited Availability; ED = Excluded Drug; ST = Step Therapy
    UseThese abbreviations indicate coverage and documentation requirements per entry
    Where foundAppears in the Requirements/Limits column for each drug
    QL (low importance)
    QL units examplesEA per 30 days; GM per 30 days; ML per 30 days (e.g., ARNUITY ELLIPTA QL 30 EA per 30 days; olopatadine nasal QL 30.5 GM per 30 days)
    PA noteMany Tier 5 specialty agents require PA in addition to QL
    B/D noteSome inhalation or infusion products flagged B/D indicate site/benefit rules

    Step Therapy Rules & References

    Step therapy statementCoverage label
    Prior trial of required agent(s) as specified by formulary step therapy rulesStep therapy may be required; coverage contingent on meeting ST requirements as described in the formulary
    If required ST is not met, Priority Health Medicare may not cover the requested drugStep therapy enforcement may lead to denial without meeting trial requirements
    Members or prescribers can request an exception to step therapy requirements per the formulary exception processExceptions available; prescriber must provide supporting medical statement
    Step therapy statementCoverage label
    Members may be required to try specified preferred drugs before coverage of non-preferred agentsST may require trial of preferred agents prior to covering alternatives
    If preferred agent fails or is not tolerated, the next agent may be covered per formulary rulesCoverage contingent on documented failure/intolerance to preferred agent
    Step therapy statementCoverage label
    Must meet step therapy prior to coverage of listed non-preferred agentSpecific agents (e.g., FETZIMA, vilazodone) are annotated with ST and QL where applicable
    Claims for non-preferred agents with ST will require evidence of prior trial of required agent(s)Coverage may be denied without documentation of prior trial
    Step therapy statementCoverage label
    'ST' (Step Therapy) appears in the formulary abbreviation keyST is defined in the legend but not applied to specific agents in this extract
    Where ST is indicated on full formulary, those rules apply; this excerpt contains no detailed ST stepsNo specific step rules present in this partial extract
    Step therapy statementCoverage label
    Paliperidone ER oral tablet extended release entries note Step Therapy (ST)Paliperidone ER formulations list Requirements/Limits = ST; QL values also specified
    Coverage for paliperidone ER requires meeting the ST requirement noted in the formularyFailure to meet ST may result in noncoverage
    Step therapy statementCoverage label
    Step therapy is referenced among the abbreviations (ST) in the formulary legendST abbreviation present but specific step requirements not listed in this excerpt
    Step therapy statementCoverage label
    Calcitriol external is listed with Requirements/Limits = STCalcitriol external is subject to step therapy per the formulary entry
    Step therapy statementCoverage label
    Step Therapy (ST) is designated on select topical products (example: calcitriol external)Where ST is listed on product entries, members must meet the ST requirement for coverage
    Step therapy statementCoverage label
    The formulary uses 'ST' in the abbreviation key indicating Step Therapy is a managed controlThis partial extract does not contain the specific step therapy sequences or required agents
    Step therapy statementCoverage label
    ST is indicated in the legend and is a recognized utilization controlNo specific step therapy rules are shown for most drugs within this extract
    Step therapy statementCoverage label
    Formulary legend includes ST (Step Therapy) among requirement abbreviationsSpecific ST requirements are absent from these provided chunks; consult full formulary for details

    Quantity Limits by Product / Strength

    XARELTO 10MG example — 30 tablets per prescription
    XARELTO 10 mg example30 tablets per 30‑day prescription (QL 30 EA per 30 days) — example provided in formulary overview
    Where referencedListed as illustrative QL in the general coverage/restrictions section
    EnforcementClaims exceeding this QL may be denied absent authorization
    Various QL examples (30/60/90/235.2 ML/900 ML/80 EA etc.)
    Mixed QL examples (EA/ML/GM)30/60/90 EA per 30 days; 235.2 ML per 28 days; 900–1200 ML per 30 days; 80 EA per 30 days — examples shown across drug classes
    Opioid/analgesic examplesHydromorphone ER QL 60 EA per 30 days; morphine solutions QL 900 ML per 30 days
    Topical/systemic examplesDiclofenac external solution QL 750 ML per 30 days; tacrolimus ointment QL 100 GM per 30 days
    eslicarbazepine acetate (200/400 mg) — 30 EA
    Eslicarbazepine 200/400 mgQL 30 EA per 30 days
    Eslicarbazepine 600/800 mgQL 60 EA per 30 days
    Formulary tierListed as Tier 5 for eslicarbazepine acetate in formulary entries
    eslicarbazepine acetate (600/800 mg) — 60 EA
    Eslicarbazepine 600/800 mgQL 60 EA per 30 days
    Dose relationshipHigher strength presentation has larger QL compared with lower strengths
    PA annotationPA applies for certain strengths as indicated in formulary entries
    lacosamide oral solution — 1200 ML
    Lacosamide oral solution QLQL 1200 ML per 30 days
    Lacosamide tablet QLQL 60 EA per 30 days for tablets
    Class noteDifferent formulations (solution vs tablet) have distinct QLs
    donepezil 10 mg tablet — 60 EA
    Donepezil 10 mg tabletQL 60 EA per 30 days
    Donepezil 5 mg tabletQL 30 EA per 30 days
    Formulation noteDispersible and other formulations have corresponding QLs listed separately
    AUVELITY — 60 EA
    AUVELITY QLQL 60 EA per 30 days
    PA/NE statusAUVELITY noted with PA and NE where applicable in formulary segment
    TieringListed as Tier 5 specialty in antidepressant segment where indicated
    AIMOVIG — 1 ML
    AIMOVIG QLQL 1 ML per 30 days
    EMGALITY QLQL 2–3 ML per 30 days depending on dose
    NURTEC QLQL 18 EA per 30 days for NURTEC
    VALCHLOR — 60
    VALCHLOR QLQL 60 GM per 30 days
    VALCHLOR designationsListed with PA and LA where applicable (topical mechlorethamine)
    Oncology topical noteTopical oncology agents have GM-based QLs in formulary
    abiraterone acetate — 120
    Abiraterone acetate QLQL 120 EA per 30 days
    TieringListed as Tier 5 in antiandrogens section
    Related agentsOther antiandrogens have QLs noted (e.g., XTANDI QL 120 EA per 30 days for some strengths)
    XPOVIO (various regimens) — 4-32
    XPOVIO regimen QL rangeQL range 4–32 EA per 28 days depending on specific therapy pack/regimen
    Pack examples40 mg once weekly — QL 8 EA per 28 days; 80 mg twice‑weekly regimens have higher QLs as listed per pack
    PA requirementXPOVIO entries list PA in addition to QL
    RYBELSUS — 30
    RYBELSUS QLQL 30 EA per 30 days
    SYNJARDY XR QLQL 30 or 60 EA per 30 days depending on strength
    TRULICITY QLQL 2 ML per 28 days (injectable) where specified
    SYNJARDY XR (various strengths) — 30 or 60
    SYNJARDY XR strengths QLQL 30 EA per 30 days for some strengths; QL 60 EA per 30 days for other strengths
    Formulary noteStrength‑dependent QLs shown in requirements/limits column
    DocumentationProviders should document dose/strength when requesting overrides
    XARELTO oral suspension reconstituted — 620
    XARELTO suspension QLQL 620 ML per 30 days (oral suspension reconstituted)
    XARELTO tablet QLs10 mg tablets — QL 30 EA per 30 days; 15 mg/2.5 mg — QL 60 EA per 30 days
    Starter pack QLXARELTO starter pack — QL 51 EA per 30 days
    enoxaparin prefilled syringes — varies by strength
    Enoxaparin prefilled syringes QLQL varies by strength — examples: 60 ML, 48 ML, 18 ML per 30 days depending on syringe strength
    Formulary designationEnoxaparin entries list QL per specific concentration/volume
    Home Infusion noteSome parenteral anticoagulant products may have HI designation where applicable
    benazepril 5 mg tablet — 480
    Benazepril 5 mg QLQL 480 EA per 30 days
    Benazepril 20 mg QLQL 120 EA per 30 days
    Dose‑dependent QLsMultiple ACE inhibitor strengths list specific QLs in formulary entries
    benazepril 20 mg tablet — 120
    Benazepril 20 mg QLQL 120 EA per 30 days
    Comparative QLLower strength (5 mg) has higher QL to allow for titration; verify strength when dispensing
    Formulary noteSee requirements/limits column for strength‑specific QLs
    REPATHA — 2 ML (formulations QL details)
    REPATHA (various presentations)QL varies by presentation: REPATHA SureClick — 2 ML per 28 days; REPATHA Pushtronex — 3.5 ML per 30 days; some presentations listed as 2 ML per 28 days
    PA requirementREPATHA entries include PA as a requirement in formulary
    Formulary tierListed as Tier 3 with PA/QL per presentation
    REPATHA Pushtronex System — 3.5 ML
    REPATHA Pushtronex QLQL 3.5 ML per 30 days
    REPATHA SureClick QLQL 2 ML per 28 days
    DocumentationPA and QL specify presentation and dosing frequency
    REPATHA SURECLICK — 2 ML
    REPATHA SureClick QLQL 2 ML per 28 days
    Other presentationsSome REPATHA formulations listed with alternative ML per period (see formulary entries)
    PA notePA required for REPATHA formulations as indicated
    ENTRESTO oral capsule sprinkle — 240
    ENTRESTO oral capsule sprinkle QLQL 240 EA per 30 days
    Formulary placementENTRESTO sprinkle listed with QL for capsule sprinkle formulation
    Clinical notePrescribers should document dose when requesting overrides
    sacubitril-valsartan 24-26 mg — 90
    sacubitril‑valsartan 24–26 mg QLQL 90 EA per 30 days
    Higher strengths QLOther sacubitril‑valsartan strengths listed with QL 60 EA per 30 days
    Tier and PAListed as Tier 3; follow Requirements/Limits column for PA if present
    rosuvastatin calcium 5/10 mg — QL 120 EA per 30 days
    rosuvastatin 5/10 mg QLQL 120 EA per 30 days
    rosuvastatin 20 mg QLQL 60 EA per 30 days
    rosuvastatin 40 mg QLQL 30 EA per 30 days
    rosuvastatin calcium 20 mg — QL 60 EA per 30 days
    rosuvastatin 20 mg QLQL 60 EA per 30 days
    Lower strength QL5/10 mg — QL 120 EA per 30 days
    Higher strength QL40 mg — QL 30 EA per 30 days
    rosuvastatin calcium 40 mg — QL 30 EA per 30 days
    rosuvastatin 40 mg QLQL 30 EA per 30 days
    Dose‑dependent limitsQL decreases as strength increases for statins in formulary examples
    Dispensing noteVerify strength when applying QL at dispensing
    REPATHA formulations QL details
    REPATHA formulations QL summarySome REPATHA presentations: 2 ML per 28 days (common), Pushtronex 3.5 ML per 30 days — PA applies
    Presentation varianceQL varies by device/presentation; check Requirements/Limits for specific presentation
    Coverage actionPA required as indicated for REPATHA entries
    Stimulant tablets/capsules — varied QL examples
    Stimulant QL variabilityStimulant tablets/capsules show varied QLs by strength/form: common examples include 30, 60, 90, 120 EA per 30 days
    ExamplesAmphetamine‑dextroamphetamine — QL 60 EA per 30 days for many strengths; some formulations QL 120 EA per 30 days
    Dispensing noteEnsure strength/form aligns with QL at claim adjudication
    Duloxetine and pregabalin QL examples
    Duloxetine QL examplesDuloxetine 20 mg — QL 180 EA per 30 days; 30 mg — QL 120 EA per 30 days; 60 mg — QL 60 EA per 30 days
    Pregabalin QL examplesPregabalin 25–200 mg — QL 90 EA per 30 days; higher strengths QL 60 EA per 30 days
    Formulation noteOral solutions list ML‑based QLs (e.g., pregabalin solution QL 900 ML per 30 days)
    Various topical and cream QL examples
    Topical/dermatologic QLsExamples include tacrolimus ointment QL 100 GM per 30 days; calcipotriene QL 120 GM/ML per 30 days; fluorouracil cream QL 40 GM per 30 days
    Other topical examplesImiquimod and various creams/solutions list GM or ML per 30 days limits
    Dermatologic PA/ED notesSome topical products are PA or ED as indicated in entries (e.g., RENOVA — ED)
    VYNDAMAX — 30
    VYNDAMAX QLQL 30 EA per 30 days
    PA requirementListed with PA in formulary entry
    Therapeutic classListed under digestive/enzyme agents in formulary
    fesoterodine fumarate ER — 30
    fesoterodine ER QLQL 30 EA per 30 days
    MYRBETRIQ QLMYRBETRIQ oral suspension — QL 300 ML per 30 days; tablet — QL 30 EA per 30 days
    Formulary placementListed under genitourinary/antispasmodic agents
    MYRBETRIQ (suspension/tablet) — 300 ML or 30 EA
    MYRBETRIQ suspension QLQL 300 ML per 30 days
    MYRBETRIQ tablet QLQL 30 EA per 30 days
    Formulary noteDifferent presentations have ML vs EA QLs
    COSENTYX — 8 ML per 28 days
    COSENTYX QLQL 8 ML per 28 days
    Presentation noteApplies to COSENTYX 300 mg presentations listed in formulary
    PA requirementPA indicated for COSENTYX entries
    DUPIXENT — 3.42 ML or 8 ML
    DUPIXENT QL optionsQL 3.42 ML or 8 ML per 30 days depending on formulation (200 mg/1.14 mL vs 300 mg/2 mL presentations)
    PA requirementDUPIXENT entries list PA in addition to QL
    Presentation specificsDifferent auto‑injector/prefilled syringe presentations have distinct QLs
    SKYRIZI — 1 ML per 28 days
    SKYRIZI QLQL 1 ML per 28 days (or 1.2/2.4 ML per 56 days for cartridge presentations)
    Presentation varianceCartridge dosing schedules list QL per 56 days accordingly
    PA requirementSKYRIZI entries include PA as indicated
    ciprofloxacin-hydrocortisone — 7.5 ML
    ciprofloxacin‑hydrocortisone QLQL 7.5 ML per 30 days
    Otic categoryListed under otic/topical anti‑infectives with GM/ML QLs
    Dispense noteVerify formulation (solution vs suspension) when applying QL
    olopatadine hcl nasal — 30.5 GM
    olopatadine nasal QLQL 30.5 GM per 30 days
    Allergy/respiratory categoryOlopatadine listed under antihistamines/nasal therapies
    Formulary noteCheck Requirements/Limits column for exact GM per period
    ARNUITY ELLIPTA — 30 EA
    ARNUITY ELLIPTA QLQL 30 EA per 30 days
    Inhaled corticosteroid categoryListed with NE for some presentations and B/D for others where specified
    Formulary updateSee Requirements/Limits for delivery/presentation specifics
    epinephrine auto-injector — 4 EA
    Epinephrine auto‑injector QLQL 4 EA per 30 days
    Pack sizesApplies to auto‑injector devices (0.15 mg/0.3 mL and 0.3 mg/0.3 mL)
    Coverage implicationQL enforced per 30‑day period; additional units require authorization
    KALYDECO — 56 EA
    KALYDECO QLQL 56 EA per 28 days
    CF agents requiring PAKALYDECO listed with PA; QL applies per 28‑day period
    Therapy pack examplesTRIKAFTA therapy pack QL 84 EA per 28 days (different pack forms listed)
    TRIKAFTA therapy pack — 84 EA
    TRIKAFTA therapy pack QLQL 84 EA per 28 days (therapy pack) — PA applies
    Alternate pack QLOther TRIKAFTA pack listing QL 56 EA per 28 days in formulary
    Coverage notePA and QL enforced for CF therapy packs as indicated
    FASENRA PEN / prefilled syringe — 1 ML
    FASENRA pen/syringe QLQL 1 ML per 30 days
    PresentationFASENRA prefilled syringe/pen listed with PA and QL per 30 days
    AdministrationInjectable biologic — follow PA and QL for coverage
    ADEMPAS — 90 EA
    ADEMPAS QLQL 90 EA per 30 days
    PA/LA statusADEMPAS listed with PA; LA where applicable
    Therapeutic classPulmonary antihypertensive — check Requirements/Limits for dosing
    OFEV — 60 EA
    OFEV QLQL 60 EA per 30 days
    PA/LAOFEV listed with PA and LA designations in formulary
    Pulmonary fibrosis classPA and QL apply to OFEV as a specialty antifibrotic agent

    Site of Care / Benefit Designations

    Note

    Contact CustomerCare for HI (Home Infusion) coverage/billing

    Drugs labeled HI (Home Infusion) may be covered under the medical benefit; providers should contact Customer Care for site‑of‑care and billing guidance.

    • Example: vancomycin IV presentations list Requirements/Limits = HI.
    • Contact CustomerCare at 844.403.0847 for Home Infusion coverage details.
    Billing Rule

    Tier 5 specialty drugs limited to 30‑day supply at pharmacy

    Tier and supply rules apply at the pharmacy level — Tier 5 (Specialty) drugs are limited to a 30‑day supply only; ensure prescriptions and claims reflect this supply rule.

    • Note: Tier 5 drugs are 30‑day supply only as indicated in the formulary notes.
    Note
    Billing Rule

    Verify HI designation and site‑of‑care for injectables/infusions

    Some injectable or infusion products have an HI designation and may be covered under the medical benefit; prescribers should verify site‑of‑care and billing requirements before ordering.

    • Example: furosemide injection — Requirements/Limits = HI. Verify medical benefit coverage and billing process prior to dispensing.

    Biosimilars & Interchangeable Biologics

    Note

    Monitor formulary updates for biosimilar additions and tier changes

    Formulary may add biosimilars or interchangeable biosimilars; when added, the brand/original biologic may move to a different tier or have new restrictions — prescribers should check formulary updates.

    • Interchangeable biosimilars may be substituted per state law without a new prescription where allowed.
    • Formulary changes are posted monthly and may affect biologic tiering or restrictions.